Últimas noticias sobre Stryker (NYSE:SYK) Bolsa

Stryker

Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Just over one fourth of Stryker's total revenue currently comes from outside the United States.

Stryker Corp

SOLITON SYSTEMS KK ORD by Soliton Systems

Soliton Systems KK

SKY NETWORK TV by Sky Network Television Ltd.

Sky Network Television Ltd

JMP Securities analyst David Turkaly reiterates Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) from Market Perform to Market Perform.

News

Reiteration

Analyst Ratings

JMP Securities Reiterates Market Perform on Strykerto Market Perform

RBC Capital analyst Shagun Singh reiterates Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Outperform and maintains $425 price target.

Price Target

RBC Capital Reiterates Outperform on Stryker, Maintains $425 Price Target

On Monday, Stryker&nbsp;Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) agreed to acquire Inari Medical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NARI#NASDAQ">NARI</a>) for $80 per share in cash, representing a total fully diluted equity value of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42830635/stryker-announces-definitive-agreement-to-acquire-inari-medical-inc-providing-entry-into-high-grow" rel="noreferrer noopener">approximately $4.9 billion</a>.
Inari, founded in 2011, will help strengthen the peripheral vascular position in the growing segment of venous thromboembolism (VTE) to Stryker.
VTE is&nbsp;a term for blood clots in the veins, which can lead to serious illness, disability, or death.
Inari&#8217;s product portfolio complements Stryker&#8217;s Neurovascular business and includes mechanical thrombectomy solutions for peripheral vascular diseases such as deep vein thrombosis and pulmonary embolism.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42274583/morgan-stanley-maintains-positive-medtech-outlook-despite-setbacks-in-2024-upgrades-intuitive-surgical-and-stryker-downgrades-nevro-and-glaukos" rel="noreferrer noopener">Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos</a>
Each year, VTE impacts up to 900,000 lives in the United States, with even more affected worldwide. Mechanical thrombectomy for VTE is an estimated $6 billion segment opportunity in the U.S. and is expected to grow 20%+ annually.
Inari products are sold in 30+ countries, with 150,000+ patients treated for VTE.
Analysts estimate Inari&#8217;s 2024 sales of around $603 million, reflecting 20%+ growth from 2023
People are at particularly high risk for this condition during or just after a hospitalization (with or without surgery), during cancer treatment, and during or just after pregnancy.
Inari provides solutions for VTE clot removal without the use of thrombolytic drugs.
&#8220;The acquisition of Inari expands Stryker&#8217;s portfolio to provide life-saving solutions to patients who suffer from peripheral vascular diseases,&#8221; said Kevin Lobo, Chair and CEO of Stryker. &#8220;These innovations elevate the standard of care for venous thromboembolism patients and will accelerate Stryker&#8217;s impact in endovascular procedures.&#8221;
The <a target="_blank" href="https://s22.q4cdn.com/857738142/files/doc_presentations/2025/Jan/06/Acquisition-of-Inari-Medical.pdf" rel="noreferrer noopener">transaction</a> will be funded with cash on hand and debt and is expected to close by the end of the first quarter of 2025.
Expected impacts to 2025 financial results will be discussed on Stryker&#8217;s upcoming fourth quarter 2024 earnings call scheduled for January 28, 2025.
Price Action: NARI stock is up 21% at $78.65, and SYK stock is down 1.76% at $355 during the premarket session at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/01/42827918/viking-therapeutics-structure-therapeutics-positioned-as-key-pharma-partners-for-weight-loss-products-analyst" target="_blank" rel="noreferrer noopener">Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst</a></li>
</ul>

Large Cap

Health Care

Movers

Trading Ideas

General

NARI

Stryker To Buy Inari Medical In $5 Billion Deal To Bolster Venous Thromboembolism Position

Needham analyst Mike Matson reiterates Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Buy and maintains $442 price target.

Needham Reiterates Buy on Stryker, Maintains $442 Price Target

Shares of Inari Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NARI#NASDAQ">NARI</a>) rose sharply in today's pre-market trading after Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) announced plans to acquire the company for <a href="https://www.benzinga.com/quote/NARI/news">$80 per share in cash.</a>
Inari Medical shares jumped 21.2% to $78.79 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>MultiSensor AI Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSAI#NASDAQ">MSAI</a>) gained 101% to $4.02 in pre-market trading after the company announced management appointments.</li>
<li>Algorhythm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIME#NASDAQ">RIME</a>) gained 86.3% to $0.2697 in pre-market trading after surging 30% on Monday.</li>
<li>XTI Aerospace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTIA#NASDAQ">XTIA</a>) rose 61.9% to $0.1425 in pre-market trading after gaining around 113% on Monday.</li>
<li>Healthy Choice Wellness Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWC#NASDAQ">HCWC</a>) rose 51.5% to $1.47 in pre-market trading after falling 12% on Monday. The company reported fourth-quarter financial results.</li>
<li>Aurora Innovation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) rose 47.1% to $9.59 in pre-market trading after the company partnered with Continental and NVIDIA to launch next-generation driverless trucks by 2027.</li>
<li>DatChat, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DATS#NASDAQ">DATS</a>) gained 34.1% to $2.63 in pre-market trading.</li>
<li>Getty Images Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GETY#NYSE">GETY</a>) gained 30.8% to $3.36 in pre-market trading. Getty Images and Shutterstock announced a merger agreement for $3.7 billion.</li>
<li>Conduit Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) gained 17.3% to $0.0848 in pre-market trading. Conduit Pharmaceuticals, last month, announced it entered an agreement with Sarborg to leverage AI and its cybernetics platform to evaluate key deliverables across multiple areas of operations.</li>
<li>Syra Health Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) gained 16.3% to $0.5700 in pre-market trading after gaining 9% on Monday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Boxlight Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOXL#NASDAQ">BOXL</a>) fell 25.6% to $1.25 in pre-market trading after jumping 265% on Monday.</li>
<li>Splash Beverage Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBEV#NASDAQ">SBEV</a>) fell 21.5% to $0.2120 in pre-market trading after jumping around 13% on Monday.</li>
<li>CytoMed Therapeutics Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDTC#NASDAQ">GDTC</a>) shares fell 20.8% to $2.72 in pre-market trading. CytoMed Therapeutics announced it entered into a business and research collaboration agreement with Mumbai-based SunAct Cancer Institute.</li>
<li>Babcock &amp; Wilcox Enterprises, (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWNB#NYSE">BWNB</a>) fell 19.1% to $17.00 in today's pre-market trading.</li>
<li>Gold Resource Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GORO#NYSE">GORO</a>) fell 17.7% to $0.1880 in pre-market trading after announcing a $2.5 million registered direct offering.</li>
<li>Kuke Music Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KUKE#NYSE">KUKE</a>) shares fell 17.2% to $0.5549 in pre-market trading.</li>
<li>Acelyrin, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRN#NASDAQ">SLRN</a>) dipped 15.4% to $2.95 in pre-market trading. ACELYRIN announced additional Phase 2 data and the Phase 3 program design for lonigutamab in Thyroid Eye Disease.</li>
<li>Cogent Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COGT#NASDAQ">COGT</a>) shares tumbled 13.2% to $7.00 in pre-market trading.</li>
<li>BP Prudhoe Bay Royalty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BPT#NYSE">BPT</a>) shares dipped 12.1% to $0.6789 in pre-market trading as the company announced no unit payment for the fourth quarter.</li>
<li>Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) declined 8.9% to $11.70 in pre-market trading after dipping more than 10% on Monday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42838883/rpm-international-cal-maine-foods-and-3-stocks-to-watch-heading-into-tuesday">RPM International, Cal-Maine Foods And 3 Stocks To Watch Heading Into Tuesday</a></li>
</ul>

BOXL

BWNB

COGT

DATS

GDTC

GETY

GORO

HCWC

KUKE

Infrared Cameras Holdings, Inc. - Common Stock

MSAI

RIME

SBEV

SLRN

SYRA

XCUR

XTIA

Why Inari Medical Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket

Stryker To Acquire Inari Medical For $80/Share In Cash

Stryker Corp  Is Nearing A Deal To Acquire Inari Medical, Sources Say

Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) has outperformed the market over the past 20 years by 2.09% on an annualized basis producing an average annual return of 10.48%. Currently, Stryker has a market capitalization of $137.65 billion. 
Buying $100 In SYK: If an investor had bought $100 of SYK stock 20 years ago, it would be worth $730.67 today based on a price of $361.08 for SYK at the time of writing.
<h3>Stryker's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1735938015_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Stryker Stock In The Last 20 Years

In a new SEC filing on January 2, it was revealed that Boehnlein, VP at Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), executed a significant exercise of company stock options.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000310764/000031076425000002//Archives/edgar/data/310764/000031076425000002/0000310764-25-000002-index.htm">U.S. Securities and Exchange Commission</a> on Thursday revealed that Boehnlein, VP at Stryker in the Health Care sector, exercised stock options for 300 shares of SYK stock. The exercise price of the options was $122.51 per share.
During Friday's morning session, Stryker shares up by 0.66%, currently priced at $361.08. Considering the current price, Boehnlein's 300 shares have a total value of $71,571.
<h3>All You Need to Know About Stryker</h3>
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Just over one fourth of Stryker's total revenue currently comes from outside the United States.
<h3>Financial Insights: Stryker</h3>
Revenue Growth: Stryker displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 11.92%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Insights into Profitability:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 64.02%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Stryker's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 2.18.
</li>
</ul>
Debt Management: Stryker's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.77, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Valuation Metrics: A Closer Look
<ul>
<li>
Price to Earnings (P/E) Ratio: Stryker's P/E ratio of 38.45 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 6.28 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio lower than industry benchmarks at 27.23, Stryker presents an attractive value opportunity.
</li>
</ul>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Understanding the Significance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>A Deep Dive into Insider Transaction Codes</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000310764">Check Out The Full List Of Stryker's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Insider Activity Update: Glenn S Boehnlein Executes Options Exercise, Resulting In $71K At Stryker

Glenn S Boehnlein, VP at Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), reported a large exercise of company stock options on December 30, according to a new SEC filing.
What Happened: Boehnlein, VP at Stryker, exercised stock options for 2,000 shares of SYK stock. This information was disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000310764/000031076424000125//Archives/edgar/data/310764/000031076424000125/0000310764-24-000125-index.htm">U.S. Securities and Exchange Commission</a> on Monday. The exercise price of the options was $122.51 per share.
Stryker shares are currently trading up by 0.25%, with a current price of $362.34 as of Tuesday morning. This brings the total value of Boehnlein's 2,000 shares to $479,659.
<h3>Unveiling the Story Behind Stryker</h3>
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Just over one fourth of Stryker's total revenue currently comes from outside the United States.
<h3>Understanding the Numbers: Stryker's Finances</h3>
Revenue Growth: Over the 3 months period, Stryker showcased positive performance, achieving a revenue growth rate of 11.92% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Interpreting Earnings Metrics:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 64.02%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Stryker's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 2.18.
</li>
</ul>
Debt Management: With a high debt-to-equity ratio of 0.77, Stryker faces challenges in effectively managing its debt levels, indicating potential financial strain.
Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 38.83 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 6.35 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Indicated by a lower-than-industry-average EV/EBITDA ratio of 27.48, the company suggests a potential undervaluation, which might be advantageous for value-focused investors.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Activity Matters in Finance</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>A Deep Dive into Insider Transaction Codes</h3>
Navigating through the landscape of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, precisely detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000310764">Check Out The Full List Of Stryker's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Glenn S Boehnlein At Stryker Executes Options Exercise, Realizing $479K

Truist Securities analyst Richard Newitter maintains Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Hold and raises the price target from $380 to $409.

Truist Securities Maintains Hold on Stryker, Raises Price Target to $409

Stryker's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) short percent of float has fallen 11.36% since its last report. The company recently reported that it has 4.24 million shares sold short, which is 1.17% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.25 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Stryker Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734363022_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Stryker has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Stryker's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Stryker's peer group average for short interest as a percentage of float is 3.89%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Stryker?

Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) has outperformed the market over the past 10 years by 3.21% on an annualized basis producing an average annual return of 14.51%. Currently, Stryker has a market capitalization of $143.03 billion. 
Buying $1000 In SYK: If an investor had bought $1000 of SYK stock 10 years ago, it would be worth $3,942.99 today based on a price of $375.20 for SYK at the time of writing.
<h3>Stryker's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734363015_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Stryker Stock In The Last 10 Years

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Deutsche Bank increased the price target for PepsiCo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) from $179 to $184. Deutsche Bank analyst Steve Powers upgraded the stock from Hold to Buy. PepsiCo shares closed at $156.77 on Wednesday. See how other analysts view this stock.</li>
<li>Wells Fargo raised the price target for The Kroger Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) from $70 to $73. Wells Fargo analyst Edward Kelly maintained an Overweight rating. Kroger shares closed at $61.33 on Wednesday. <a href="https://www.benzinga.com/quote/KR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Oppenheimer boosted the price target for KKR &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) from $153 to $175. Oppenheimer analyst Chris Kotowski maintained an Outperform rating. KKR shares closed at $157.39 on Wednesday. <a href="https://www.benzinga.com/quote/KKR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho raised Lowe&#8217;s Companies, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) price target from $282 to $305. Mizuho analyst David Bellinger maintained an Outperform rating. Lowe&#8217;s shares settled at $267.90 on Wednesday. <a href="https://www.benzinga.com/quote/LO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies slashed Adobe Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) price target from $700 to $650. Jefferies analyst Brent Thill maintained a Buy rating. Adobe shares closed at $549.93 on Wednesday. <a href="https://www.benzinga.com/quote/ADBE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Roth MKM raised United Natural Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNFI#NYSE">UNFI</a>) price target from $20 to $26. Roth MKM analyst Bill Kirk maintained a Neutral rating. United Natural Foods shares closed at $28.08 on Wednesday.  <a href="https://www.benzinga.com/quote/UNFI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel cut Match Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) price target from $39 to $36. Stifel analyst Mark Kelley maintained a Hold rating on the stock. Match Group shares closed at $61.48 on Wednesday. See how other analysts view this stock.</li>
<li>UBS cut the price target for Commercial Metals Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMC#NYSE">CMC</a>) from $62 to $56. UBS analyst Curt Woodworth downgraded the stock from Buy to Sell. Commercial Metals shares settled at $61.60 on Wednesday. <a href="https://www.benzinga.com/quote/CMC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank boosted Keurig Dr Pepper Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDP#NASDAQ">KDP</a>) price target from $37 to $39. Deutsche Bank analyst Steve Powers upgraded the stock from Hold to Buy. Keurig Dr Pepper shares closed at $33.26 on Wednesday. <a href="https://www.benzinga.com/quote/KDP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham raised Stryker Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) price target from $409 to $442. Needham analyst Mike Matson maintained a Buy rating. Stryker shares closed at $376.16 on Wednesday. <a href="https://www.benzinga.com/quote/SYK/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying PEP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="568" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12101330/image-105-1024x568.png" alt="" class="wp-image-689663" style="width:632px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12101330/image-105-1024x568.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12101330/image-105-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12101330/image-105-768x426.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12101330/image-105.png 1117w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42437595/jim-cramer-says-keep-owning-this-energy-stock-abbott-laboratories-legal-stuff-is-behind-them">Jim Cramer Says &#8216;Keep Owning&#8217; This Energy Stock, Abbott Laboratories &#8216;Legal Stuff&#8217; Is Behind Them</a></li>
</ul>

Markets

ADBE

MTCH

UNFI

PepsiCo To Rally Over 17%? Here Are 10 Top Analyst Forecasts For Thursday

Needham analyst Mike Matson maintains Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Buy and raises the price target from $409 to $442.

Needham Maintains Buy on Stryker, Raises Price Target to $442

Citigroup analyst Joanne Wuensch maintains Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Buy and raises the price target from $411 to $450.

Citigroup Maintains Buy on Stryker, Raises Price Target to $450

RBC Capital analyst Shagun Singh reiterates Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Outperform and raises the price target from $400 to $425.

RBC Capital Reiterates Outperform on Stryker, Raises Price Target to $425

Wells Fargo analyst Larry Biegelsen maintains Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Overweight and raises the price target from $405 to $427.

Wells Fargo Maintains Overweight on Stryker, Raises Price Target to $427

Last year, Morgan Stanley upgraded its outlook for the U.S. MedTech sector to &#8220;Attractive,&#8221; believing the concerns around GLP-1s were already reflected in stock prices and that fundamentals were strong.
However, this view didn&#8217;t play out as expected, mainly due to unforeseen, company-specific issues, such as DexCom, Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) unexpected <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39988466/dexcom-faces-short-term-challenges-but-market-growth-prospects-remain-strong-analys" rel="noreferrer noopener">Q2 channel mix challenges</a>, Edwards Lifesciences Corporation&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39967649/edwards-lifesciences-stock-tumbles-highlights-slowdown-in-tavr-business" rel="noreferrer noopener">slowdown in TAVR procedures</a>, TransMedics Group, Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41608129/organ-transplant-medtech-transmedics-q3-performance-disappoints-analyst-outlines-in" rel="noreferrer noopener">seasonal impacts</a>, and iRhythm Technologies, Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>) <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41462205/with-fda-approval-irhythm-may-be-able-to-lift-regulatory-overhang-investor-skeptici" rel="noreferrer noopener">DOJ investigation</a>.
Morgan Stanley is bullish on the MedTech industry as volumes and pipelines continue to be strong into 2025 despite a shakey 2024.
The analyst also adds that MedTech seems less exposed to potential delays from extended FDA regulatory pathways than other healthcare sectors, given its lower reliance on PMAs and clinical-trial-heavy products.
The analyst adds that while single-stock surprises are inevitable, the overall outlook for the sector heading into 2025 remains favorable.
Morgan Stanley upgraded the outlook on Intuitive Surgical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) and Stryker Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), moving both to Overweight from Equal-weight, citing:
<ul>
<li>ISRG: Strong demand for the Da Vinci Dv5 system is expected to exceed market expectations for <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41406234/intuitive-surgical-posts-q3-earnings-beat-these-analysts-raise-forecasts-on-dv5-upt" target="_blank" rel="noreferrer noopener">installed base growth</a>.</li>
<li>SYK: While orthopedic procedure volumes face some uncertainty, an estimated $1 billion—$2 billion backlog could drive growth in 2025. The company also benefits from ongoing M&amp;A opportunities <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40819730/stryker-unveils-new-foot-ankle-solutions-with-truss-implants-details" target="_blank" rel="noreferrer noopener">and product innovations</a>.</li>
</ul>
Additional updates:
<ul>
<li>Procept BioRobotics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>): Initiated at Overweight, driven by increasing demand and higher pricing for Hydros in operating room efficiency, particularly in <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41583831/surgical-robotics-provider-procept-biorobotics-q3-earnings-beats-street-view-analys" target="_blank" rel="noreferrer noopener">lower-volume BPH centers</a>.</li>
<li>Tandem Diabetes Care Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>): Upgraded to Overweight with a $45 price target, as its valuation (below 2x sales) seems overly compressed. Expansion into type 2 diabetes in 2025 could double its <a href="https://www.benzinga.com/news/24/10/41148635/tandem-diabetes-insulin-pump-demand-to-surge-despite-popular-demand-of-weight-loss-drugs-bullish-ana" target="_blank" rel="noreferrer noopener">total addressable market</a>.</li>
<li>Globus Medical Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>): Upgraded to Overweight with a $100 price target as merger concerns ease and strong above-market growth persists.</li>
<li>Embecta Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>): Raised to Equal-weight from Underweight, factoring in the discontinuation of certain risks and potential upside from GLP-1 <a href="https://www.benzinga.com/news/24/10/41148635/tandem-diabetes-insulin-pump-demand-to-surge-despite-popular-demand-of-weight-loss-drugs-bullish-ana" target="_blank" rel="noreferrer noopener">pen needle demand</a>.</li>
</ul>
The analyst is more cautious about Glaukos Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>), downgrading it to Underweight from Equal-weight. The analyst notes that iDose is a strong product with promising long-term potential, but the current valuation limits the upside compared to other stocks. Additionally, although the pipeline includes exciting projects like Wet AMD, they remain <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41752463/glaukos-reports-30-boost-in-glaucoma-sales-improved-margins-in-q3-analyst-highlights-certain-headwi" rel="noreferrer noopener">years away from fruition</a>.
Morgan Stanley has downgraded Nevro Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) to Underweight from Equal-weight. Despite trading near record lows, the analyst expects weak demand for spinal cord stimulation devices to persist, with limited <a target="_blank" href="https://www.benzinga.com/general/health-care/24/11/41910770/why-medical-device-firm-nevro-stock-is-trading-higher-on-tuesday" rel="noreferrer noopener">opportunities for cost reductions</a>.
The analyst remains cautious about STAAR Surgical Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>). While the company is executing well, it faces tough conditions in the refractive surgery market, particularly in China and the U.S.
Lastly, Morgan Stanley is cautious about Baxter International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) because it offers fewer upside opportunities than peers and has a more conservative outlook <a target="_blank" href="https://www.benzinga.com/general/health-care/24/11/41845345/baxter-expects-hurricane-helene-aftermath-to-impact-near-term-financial-outlook" rel="noreferrer noopener">on operating margins</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42270388/marvell-and-aws-deepen-collaboration-on-cloud-and-ai-solutions-driving-stock-surge-ahead-of-q3-earnings" target="_blank" rel="noreferrer noopener">Marvell And AWS Deepen Collaboration On Cloud And AI Solutions: Details</a></li>
</ul>
Photo by metamorworks via Shutterstock

Analyst Color

Biotech

Upgrades

Downgrades

DXCM

EMBC

GKOS

GMED

IRTC

ISRG

NVRO

PRCT

STAA

TMDX

TNDM

Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos

Ratings for Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) were provided by 19 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">11</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">5</td>
<td align="right">7</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $398.89, a high estimate of $445.00, and a low estimate of $370.00. Marking an increase of 5.68%, the current average surpasses the previous average price target of $377.44. 
<img src="https://www.benzinga.com/files/images/story/2024/1733155231_0_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Stryker by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drew Ranieri</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$445.00</td>
<td>$370.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$411.00</td>
<td>$406.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$418.00</td>
<td>$402.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$394.00</td>
<td>$383.00</td>
</tr>
<tr>
<td>Kyle Rose</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$400.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$400.00</td>
<td>$386.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$420.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$420.00</td>
<td>$375.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$380.00</td>
<td>$370.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$384.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$405.00</td>
<td>$381.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$370.00</td>
<td>$366.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$405.00</td>
<td>$378.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$409.00</td>
<td>$393.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$383.00</td>
<td>$374.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$370.00</td>
<td>$345.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$380.00</td>
<td>$365.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$380.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Mike Polark</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$405.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Stryker. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Stryker compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Stryker's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Stryker's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SYK/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Stryker analyst ratings.</a>
<h2>About Stryker</h2>
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Just over one fourth of Stryker's total revenue currently comes from outside the United States.
<h3>A Deep Dive into Stryker's Financials</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Stryker's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 11.92%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Stryker's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 15.18%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 4.18%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Stryker's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 2.01%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a high debt-to-equity ratio of 0.77, Stryker faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cracking The Code: Understanding Analyst Reviews For Stryker

Penumbra spikes after Stryker- Inari deal

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Paychex (PAYX) agreed to acquire Payco...

Paychex to acquire Paycor HCM, Getty and Shutterstock to merge: Morning Buzz

BTIG analyst Ryan Zimmerman maintained a Buy rating on Stryker (SYK – Research Report) yesterday and set a price target of $394.00. The company's s...

BTIG Sticks to Their Buy Rating for Stryker (SYK)

Wondering which stocks are trending today? TipRanks has calculated which stocks have received the greatest number of new ratings from analysts and ...

Top 3 Trending Stocks, According to Analysts – 1/8/2025

Stryker: Starting 2025 With A Bolt-On Deal For Inari Medical

Inari Gets A Fair Bid As Stryker Buys Yet Another High-Growth Asset

'Physical AI': An All-Robotics Portfolio Sleeve, Preparing For 'Thor'

Bernstein raised the firm's price target on Stryker (SYK) to $425 from $410 and keeps an Outperform rating on the shares as part of a broader resea...

Stryker price target raised to $425 from $410 at Bernstein

Terumo's Improving Growth Outlook Is Worth More Attention

Med Tech & Diagnostics Analysts Matson and Saxon, along with Dr. Kevin Cronin, Assistant Professor of Orthopaedic Surgery at the University of Sout...

Needham medtech & diagnostics analyst holds analyst/industry conference call

AMZN

APOG

CNMD

CRMD

CTAS

ENOV

ENPH

FANUF

FANUY

HNDAF

HYMTF

IRBT

KITT

KITTW

MBOT

NVDA

PAYX

PLTR

PONY

PYCR

SERV

SFTBF

SFTBY

SSTK

TOYOF

TRUMF

TRUMY

TSLA

TTAN

TTOO

UBER

ULTA

YASKF

YASKY

Screenshot 2024-09-30 at 5.38.54 PM

Movers & Shakers

COSM

Nestle Sponsored representing Registered Shares Series B

NSRGY

VTRS

How Cosmos Health&#39;s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

Screenshot 2024-03-18 at 5.30.26 PM

MGRM

Monogram Orthopaedics (NASDAQ: MGRM) Aims To Overcome Robot Shortcomings With Its Advanced Solution

Press Releases

Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors

Earnings

Stryker reports third quarter 2024 operating results

Stryker launches next generation of SurgiCount+ to help improve the standard of care in hospitals for sponge management and blood loss assessment

Stryker unveils Oculan Lighting Platform to enhance surgical visualization and illumination

Small Cap

Opinion

AI's Growing Role in Transforming Healthcare Delivers Innovations in Diagnostics, Patient Care

Dividends

Stryker declares an $0.84 per share quarterly dividend

Why Healthcare Providers Are Increasingly Trusting Artificial Intelligence for Detection & Diagnosis

Stryker to announce financial results for its fourth quarter and full year 2024

Stryker announces definitive agreement to acquire Inari Medical, Inc., providing entry into high-growth peripheral vascular segment

INARI MEDICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inari Medical, Inc. - NARI

Comments

Stryker

Noticias

Últimas noticias sobre Stryker (NYSE:SYK) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL